Human OGT/HINCUT-1/HRNT1 ORF/cDNA clone-Adeno-associate virus(AAV) plasmid (NM_181672.2)

Cat. No.: pGMAAV000104
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human OGT/HINCUT-1/HRNT1 Adeno-associated virus expression plasmid (ITR-vector) for OGT AAV packaging, OGT AAV production.The purified Human OGT/HINCUT-1/HRNT1 AAV particle serves as an invaluable asset for in-depth in vivo OGT studies, mechanism of action (MOA) research, and the evolution of OGT-associated gene therapy strategies.

Our GM-AAV ITR vector is optimized with the G-NEXT™ multi-serotypes AAV vector system. Explore the G-NEXT™ system in detail.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to OGT/HINCUT-1 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMAAV000104
Gene Name OGT
Accession Number NM_181672.2
Gene ID 8473
Species Human
Product Type Adeno-associate virus(AAV) plasmid (overexpression)
Insert Length 3141 bp
Gene Alias HINCUT-1,HRNT1,MRX106,O-GLCNAC,OGT1
Fluorescent Reporter Null
Mammalian Cell Selection Null
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGGCGTCTTCCGTGGGCAACGTGGCCGACAGCACAGAACCAACGAAACGTATGCTTTCCTTCCAAGGGTTAGCTGAGTTGGCACATCGAGAATATCAGGCAGGAGATTTTGAGGCAGCTGAGAGACACTGCATGCAGCTCTGGAGACAAGAGCCAGACAATACTGGTGTGCTTTTATTACTTTCATCTATACACTTCCAGTGTCGAAGGCTGGACAGATCTGCTCACTTTAGCACTCTGGCAATTAAACAGAACCCCCTTCTGGCAGAAGCTTATTCGAATTTGGGGAATGTGTACAAGGAAAGAGGGCAGTTGCAGGAGGCAATTGAGCATTATCGACATGCATTGCGTCTCAAACCTGATTTCATCGATGGTTATATTAACCTGGCAGCCGCCTTGGTAGCAGCGGGTGACATGGAAGGGGCAGTACAAGCTTACGTCTCTGCTCTTCAGTACAATCCTGATTTGTACTGTGTTCGCAGTGACCTGGGGAACCTGCTCAAAGCCCTGGGTCGCTTGGAAGAAGCCAAGGCATGTTATTTGAAAGCAATTGAGACGCAACCGAACTTTGCAGTAGCTTGGAGTAATCTTGGCTGTGTTTTCAATGCACAAGGGGAAATTTGGCTTGCAATTCATCACTTTGAAAAGGCTGTCACCCTTGACCCAAACTTTCTGGATGCTTATATCAATTTAGGAAATGTCTTGAAAGAGGCACGCATTTTTGACAGAGCTGTGGCAGCTTATCTTCGTGCCCTAAGTTTGAGTCCAAATCACGCAGTGGTGCACGGCAACCTGGCTTGTGTATACTATGAGCAAGGCCTGATAGATCTGGCAATAGACACCTACAGGCGGGCTATCGAACTACAACCACATTTCCCTGATGCTTACTGCAACCTAGCCAATGCTCTCAAAGAGAAGGGCAGTGTTGCTGAAGCAGAAGATTGTTATAATACAGCTCTCCGTCTGTGTCCCACCCATGCAGACTCTCTGAATAACCTAGCCAATATCAAACGAGAACAGGGAAACATTGAAGAGGCAGTTCGCTTGTATCGTAAAGCATTAGAAGTCTTCCCAGAGTTTGCTGCTGCCCATTCAAATTTAGCAAGTGTACTGCAGCAGCAGGGAAAACTGCAGGAAGCTCTGATGCATTATAAGGAGGCTATTCGAATCAGTCCTACCTTTGCTGATGCCTACTCTAATATGGGAAACACTCTAAAGGAGATGCAGGATGTTCAGGGAGCCTTGCAGTGTTATACGCGTGCCATCCAAATTAATCCTGCATTTGCAGATGCACATAGCAATCTGGCTTCCATTCATAAGGATTCAGGGAATATTCCAGAAGCCATAGCTTCTTACCGCACGGCTCTGAAACTTAAGCCTGATTTTCCTGATGCTTATTGTAACTTGGCTCATTGCCTGCAGATTGTCTGTGATTGGACAGACTATGATGAGCGAATGAAGAAGTTGGTCAGTATTGTGGCTGACCAGTTAGAGAAGAATAGGTTGCCTTCTGTGCATCCTCATCATAGTATGCTATATCCTCTTTCTCATGGCTTCAGGAAGGCTATTGCTGAGAGGCACGGCAACCTGTGCTTAGATAAGATTAATGTTCTTCATAAACCACCATATGAACATCCAAAAGACTTGAAGCTCAGTGATGGTCGGCTGCGTGTAGGATATGTGAGTTCCGACTTTGGGAATCATCCTACTTCTCACCTTATGCAGTCTATTCCAGGCATGCACAATCCTGATAAATTTGAGGTGTTCTGTTATGCCCTGAGCCCAGACGATGGCACAAACTTCCGAGTGAAGGTGATGGCAGAAGCCAATCATTTCATTGATCTTTCTCAGATTCCATGCAATGGAAAAGCAGCTGATCGCATCCATCAGGATGGAATTCATATCCTTGTAAATATGAATGGCTATACTAAGGGCGCTCGAAATGAGCTTTTTGCTCTCAGGCCAGCTCCTATTCAGGCAATGTGGCTGGGATACCCTGGGACGAGTGGTGCGCTTTTCATGGATTATATTATCACTGATCAGGAAACTTCGCCAGCTGAAGTTGCTGAGCAGTATTCCGAGAAATTGGCTTATATGCCCCACACTTTTTTTATTGGTGATCATGCTAATATGTTCCCTCACCTGAAGAAAAAAGCAGTCATCGATTTTAAGTCCAATGGGCACATTTATGACAATCGGATAGTTCTGAATGGCATCGACCTCAAAGCATTTCTTGATAGTCTACCAGATGTGAAAATTGTCAAGATGAAGTGTCCTGATGGAGGAGACAATGCAGATAGCAGTAACACAGCTCTTAATATGCCTGTTATTCCTATGAATACTATTGCAGAAGCAGTTATTGAAATGATTAACCGAGGACAGATTCAAATAACAATTAATGGATTCAGTATTAGCAATGGACTGGCAACTACTCAGATCAACAATAAGGCTGCAACTGGAGAGGAGGTTCCCCGTACCATTATTGTAACCACCCGTTCTCAGTACGGGTTACCAGAAGATGCCATCGTATACTGTAACTTTAATCAGTTGTATAAAATTGACCCTTCTACTTTGCAGATGTGGGCAAACATTCTGAAGCGTGTTCCCAATAGTGTACTCTGGCTGTTGCGTTTTCCAGCAGTAGGAGAACCTAATATTCAACAGTATGCACAAAACATGGGCCTGCCCCAGAACCGTATCATTTTTTCACCTGTTGCTCCTAAAGAGGAACACGTCAGGAGAGGCCAGCTGGCTGATGTCTGCTTGGACACTCCACTCTGTAATGGGCACACCACAGGGATGGATGTCCTCTGGGCAGGGACCCCCATGGTGACTATGCCAGGAGAGACTCTTGCTTCTCGAGTTGCAGCATCCCAGCTCACTTGCTTAGGTTGTCTTGAGCTTATTGCTAAAAACAGACAAGAATATGAAGACATAGCTGTGAAGCTGGGAACTGATCTAGAATACCTGAAGAAAGTTCGTGGCAAAGTCTGGAAGCAAAGAATATCTAGCCCTCTGTTCAACACCAAACAATACACAATGGAACTAGAGCGGCTCTATCTACAGATGTGGGAGCATTATGCAGCTGGCAACAAACCTGACCACATGATTAAGCCTGTTGAAGTCACTGAGTCAGCATAA
ORF Protein Sequence MASSVGNVADSTEPTKRMLSFQGLAELAHREYQAGDFEAAERHCMQLWRQEPDNTGVLLLLSSIHFQCRRLDRSAHFSTLAIKQNPLLAEAYSNLGNVYKERGQLQEAIEHYRHALRLKPDFIDGYINLAAALVAAGDMEGAVQAYVSALQYNPDLYCVRSDLGNLLKALGRLEEAKACYLKAIETQPNFAVAWSNLGCVFNAQGEIWLAIHHFEKAVTLDPNFLDAYINLGNVLKEARIFDRAVAAYLRALSLSPNHAVVHGNLACVYYEQGLIDLAIDTYRRAIELQPHFPDAYCNLANALKEKGSVAEAEDCYNTALRLCPTHADSLNNLANIKREQGNIEEAVRLYRKALEVFPEFAAAHSNLASVLQQQGKLQEALMHYKEAIRISPTFADAYSNMGNTLKEMQDVQGALQCYTRAIQINPAFADAHSNLASIHKDSGNIPEAIASYRTALKLKPDFPDAYCNLAHCLQIVCDWTDYDERMKKLVSIVADQLEKNRLPSVHPHHSMLYPLSHGFRKAIAERHGNLCLDKINVLHKPPYEHPKDLKLSDGRLRVGYVSSDFGNHPTSHLMQSIPGMHNPDKFEVFCYALSPDDGTNFRVKVMAEANHFIDLSQIPCNGKAADRIHQDGIHILVNMNGYTKGARNELFALRPAPIQAMWLGYPGTSGALFMDYIITDQETSPAEVAEQYSEKLAYMPHTFFIGDHANMFPHLKKKAVIDFKSNGHIYDNRIVLNGIDLKAFLDSLPDVKIVKMKCPDGGDNADSSNTALNMPVIPMNTIAEAVIEMINRGQIQITINGFSISNGLATTQINNKAATGEEVPRTIIVTTRSQYGLPEDAIVYCNFNQLYKIDPSTLQMWANILKRVPNSVLWLLRFPAVGEPNIQQYAQNMGLPQNRIIFSPVAPKEEHVRRGQLADVCLDTPLCNGHTTGMDVLWAGTPMVTMPGETLASRVAASQLTCLGCLELIAKNRQEYEDIAVKLGTDLEYLKKVRGKVWKQRISSPLFNTKQYTMELERLYLQMWEHYAAGNKPDHMIKPVEVTESA

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-MP2223-Ab Anti-OGT1/ OGT/ HINCUT-1 monoclonal antibody
    Target Antigen GM-Tg-g-MP2223-Ag OGT VLP (virus-like particle)
    ORF Viral Vector pGMLV001746 Human OGT Lentivirus plasmid
    ORF Viral Vector pGMAD000506 Human OGT Adenovirus plasmid
    ORF Viral Vector pGMAD000681 Human OGT Adenovirus plasmid
    ORF Viral Vector pGMAD001640 Human OGT Adenovirus plasmid
    ORF Viral Vector pGMAAV000104 Human OGT Adeno-associate virus(AAV) plasmid
    ORF Viral Vector pGMPC001483 Human OGT Mammalian (Non-Viral Vector) plasmid
    ORF Viral Vector pGMPC001755 Human OGT Mammalian (Non-Viral Vector) plasmid
    ORF Viral Vector vGMLV001746 Human OGT Lentivirus particle
    ORF Viral Vector vGMAD000506 Human OGT Adenovirus particle
    ORF Viral Vector vGMAD000681 Human OGT Adenovirus particle
    ORF Viral Vector vGMAD001640 Human OGT Adenovirus particle
    ORF Viral Vector vGMAAV000104 Human OGT Adeno-associate virus(AAV) particle


    Target information

    Target ID GM-MP2223
    Target Name OGT
    Gene ID 8473, 108155, 698268, 26295, 101094162, 480955, 532053, 100056148
    Gene Symbol and Synonyms 1110038P24Rik,4831420N21Rik,HINCUT-1,HRNT1,MRX106,O-GLCNAC,OGT,OGT1,Ogtl,XLID106
    Uniprot Accession O15294
    Uniprot Entry Name OGT1_HUMAN
    Protein Sub-location Transmembrane Protein
    Category Not Available
    Disease Prostate Cancer
    Gene Ensembl ENSG00000147162
    Target Classification Not Available

    This gene encodes a glycosyltransferase that catalyzes the addition of a single N-acetylglucosamine in O-glycosidic linkage to serine or threonine residues. Since both phosphorylation and glycosylation compete for similar serine or threonine residues, the two processes may compete for sites, or they may alter the substrate specificity of nearby sites by steric or electrostatic effects. The protein contains multiple tetratricopeptide repeats that are required for optimal recognition of substrates. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Oct 2009]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.